MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells

Cellular Physiology and Biochemistry

Volumn 33, Issue 5, 2014, Pages 1557-1567

  Xu, Chunyuan ^a,b   Kong, Xiaoli ^a   Wang, Haiji ^a,c   Zhang, Ning ^a   Kong, Xiangnan ^a   Ding, Xia ^a   Li, Xiaoyan ^a   Yang, Qifeng ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c Affiliated Hospital of Qingdao   (China)

Author keywords

Breast cancer; Estrogen independent growth; MTDH; PTEN; Tamoxifen resistance

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TAMOXIFEN; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; MTDH PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; MTDH PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MCF 7 CELL LINE; METADHERIN; MOUSE; MTT ASSAY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; PTEN PHOSPHOHYDROLASE; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 84901372953     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358719     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 1998;90:1371-1388. (Pubitemid 28439961)
3. Tamoxifen for early breast cancer: An overview of the randomised trials. Early breast cancer trialists' collaborative group. Lancet 1998;351:1451-1467.
4. Massarweh S, Schiff R: Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities. Clin Cancer Res 2007;13:1950-1954. (Pubitemid 46649859)
5. Ward A, Balwierz A, Zhang JD, Kublb eck M, Pawitan Y, Hielscher T, Wiemann S, Sahin O: Re-expression of microrna-375 reverses both tamoxifen resistance and accompanying emt-like properties in breast cancer. Oncogene 2013;32:1173-1182.
6. Leszczyniecka M, Kang DC, Sarkar D, Su ZZ, Holmes M, Valerie K, Fisher PB: Identification and cloning of human polynucleotide phosphorylase, hpnpase old-35, in the context of terminal differentiation and cellular senescence. Proc Natl Acad Sci U S A 2002;99:16636-16641. (Pubitemid 36034025)
7. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y: Mtdh activation by 8q22 genomic gain promotes che moresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009;15:9-20.
8. Li X, Kong X, Huo Q, Guo H, Yan S, Yuan C, Moran MS, Shao C, Yang Q: Metadherin enhances the in vasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci 2011;102:1151-1157.
9. Su P, Zhang Q, Yang Q: Immunohistochemical analysis of metadherin in proliferative and cancerous breast tissue. Diagn Pathol 2010;5:38.
10. Zhao Y, Moran MS, Yang Q, Liu Q, Yuan C, Hong S, Kong B: Metadherin regulates radioresistance in cervical cancer cells. Oncol Rep 2012;27:1520-1526.
11. Tokunaga E, Nakashima Y, Yamashita N, Hisamatsu Y, Okada S, Akiyoshi S, Aishima S, Kitao H, Morita M, Maehara Y: Overexpression of metadherin/mtdh is associated with an ag gressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer 2014;21:341-349.
12. Ao A, Morrison BJ, Wang H, Lopez JA, Reynolds BA, Lu J: Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments. PLoS One 2011;6:e18810.
13. Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA, Burow ME: Regulation of eralpha-mediated transcription of bcl-2 by pi3k-akt crosstalk: Implications for breast cancer cell survival. Int J Oncol 2010;37:541-550.
14. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: Nonendocrine pathways and endocrine resistance: Observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004;10:346S-354S. (Pubitemid 38116641)
15. Lykkesfeldt AE: Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 1996;35:S9-14.
16. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM: Akt activati on predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207:139-146. (Pubitemid 41404144)
17. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
18. Gradishar WJ: Tamoxifen-what next Oncologist 2004;9:378-384.
19. Lewis-Wambi JS, Jordan VC: Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (serms). Breast Dis 2005;24:93-105.
20. Ring A Dowsett M Mechanisms of tamoxifen resistance Endocr Relat Cancer 2004 11 643-658. (Pubitemid 40065543)
21. Beelen K, Zwart W, Linn SC: Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy Nat Rev Clin Oncol 2012;9:529-541.
22. Hortobagyi GN: Toward individualized breast cancer therapy: Translating biological concepts to the bedside. Oncologist 2012;17:577-584.
23. Li C, Liu J, Lu R, Yu G, Wang X, Zhao Y, Song H, Lin P, Sun X, Yu X, Zhang Y, Ning X, Geng J: Aeg-1 overexpression: A novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers. Int J Gynecol Cancer 2011;21 :602-608.
24. Yu C, Chen K, Zheng H, Guo X, Jia W, Li M, Zeng M, Li J, Song L: Overexpression of astrocyte elevated gene-1 (aeg-1) is associated with esophageal squamous cell carcinoma (escc) progressi on and pathogenesis. Carcinogenesis 2009;30:894-901.
25. Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet JM, Fisher PB, Sar kar D: Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009;119:465-477.
26. Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, Fishe r PB: Astrocyte elevated gene-1 (aeg-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci U S A 2009;106:21300-21305.
27. Song L, Li W, Zhang H, Liao W, Dai T, Yu C, Ding X , Zhang L, Li J: Over-expression of aeg-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. J Pathol 2009;219:317-326.
28. Li C, Li R, Song H, Wang D, Feng T, Yu X, Zhao Y, Liu J, Wang Y, Geng J: Significance of aeg-1 expression in correlation with vegf, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol 2011;103:184-192.
29. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M, Dahiya R: Knockdown of astrocyte-elevated gene-1 inhibits p rostate cancer progression through upregulation of foxo3a activity. Oncogene 2007;26:7647-7655. (Pubitemid 350224215)
30. Li J, Yang L, Song L, Xiong H, Wang L, Yan X, Yuan J, Wu J, Li M: Astrocyte elevated g ene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor foxo1. Oncogene 2009;28:3188-3196.
31. Khuda, II, Koide N, Noman AS, Dagvadorj J, Tumurkhuu G, Naiki Y, Komat su T, Yoshida T, Yokochi T: Astrocyte elevated gene-1 (aeg-1) is induced by lipopolysaccharide as toll-like receptor 4 (tlr4) ligand and regulates tlr4 signalling. Immunology 2009;128:e700-706.
32. Imagawa W, Pedc henko VK, Helber J, Zhang H: Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis. J Steroid Biochem Mol Biol 2002;80:213-230. (Pubitemid 34233741)
33. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J, Jr., Berstein L, Yue W: Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen s ensitivity. Endocr Relat Cancer 2005;12:S61-73.
34. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE: Oncogenic her2{delta}16 suppresses mir-15a/16 and deregulates bcl-2 to promote endocrine r esistance of breast tumors. Carcinogenesis 2010;31:2049-2057.
35. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, Mo YY: Microrna-101-mediated akt activation and estrogen-independent growth. Oncogene 2011;30:822-831.
36. Mandlekar S, Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-477. (Pubitemid 33078758)
37. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE: The her4/4icd estrogen receptor coactivator and bh3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 2008;68:6387-639 5.
38. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R: Reduced pten expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005;18:250-25 9. (Pubitemid 40188633)